CXCR4 promotes neuroblastoma growth and therapeutic resistance through miR-15a/16-1 mediated ERK and BCL2/cyclin D1 pathways

CXCR4 expression in neuroblastoma (NB) tumors correlates with disease severity. In this study, we describe mechanisms by which CXCR4 signaling controls NB tumor growth and response to therapy. We found that overexpression of CXCR4 or stimulation with CXCL12 supports NB tumorigenesis. Moreover, CXCR4 inhibition with the high affinity CXCR4 antagonist, BL-8040 prevented tumor growth and reduced survival of tumor cells. These effects were mediated by the upregulation of miR-15a/16-1, which resulted in downregulation of their target genes BCL-2 and cyclin D1, as well as inhibition of ERK. Overexpression of miR-15a/16-1 in cells increased cell death, whereas antagomirs to miR-15a/16-1 abolished the pro-apoptotic effects of BL-8040. CXCR4 overexpression also increased miR-15a/16-1 shifting their oncogenic dependency from the BCL-2 to the ERK signaling pathway. Overall, our results demonstrate the therapeutic potential of CXCR4 inhibition in neuroblastoma treatment and provide a rationale to test combination therapies employing CXCR4 and BCL-2 inhibitors to increase the efficacy of these agents.

http://ift.tt/2kM05rF